BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint
Go back to BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint| BIOLIFE SOLUTIONS (NASDAQ: BLFS) | Delayed: 34.66 +0.73 (2.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.93 | 52 Week High | $3.58 | |||
| Open | $34.27 | 52 Week Low | $1.43 | |||
| Day High | $34.76 | P/E | N/A | |||
| Day Low | $34.12 | EPS | $0.00 | |||
| Volume | 655,857 | |||||
| Intelligroup, Inc. (NASDAQ: TIG) | Delayed: 6.16 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.16 | 52 Week High | $0.09 | |||
| Open | $0.03 | 52 Week Low | $0.03 | |||
| Day High | $6.16 | P/E | N/A | |||
| Day Low | $6.16 | EPS | $-0.16 | |||
| Volume | 1,500 | |||||
